Sentence examples for bioavailability level from inspiring English sources

These results indicate that intestinal bioavailability, level of biotransformation, and the metabolic profile of BaP-derived products entering the blood from the intestine may be altered by dose and dietary BNF pretreatment.

The bioavailability, exposure levels and, ultimately, the toxicity profile of most compounds are influenced by the dynamic temporal and positional gradients (e.g. clearance) resulting from the inherent ADME properties of various tissues.

3T3-L1 andpoC2C12 and C2C12 myotubes were stimulated with ME to explore its bioavailability in cell level.

At the tissue level, bioavailability of IGF-1 and IGF-2 is modulated by IGFBP protease and the presence of the non-signaling, IGF-2-binding IGF-2R.

Under conditions of oxidative stress, decreased NO bioavailability and increased levels of oxidation of sGC both lead to impaired sGC activation and decreased levels of cGMP production.

SAR and QSAR methods are used to investigate adverse health effects and exposure levels, bioavailability, and pharmacokinetic properties of hazardous chemical compounds.

Cysteine is generated from Hcy, predominantly in the liver, via the transsulfuration pathway (Fig. 3A) and its bioavailability critically affects levels of hepatic GSH [46].

Despite the promise of curcumin as a chemopreventive and cancer-selective therapeutic agent, clinical trials have revealed that curcumin suffers from poor absorption, low bioavailability, low plasma levels, rapid metabolism and quick elimination from the body.

An earlier study showed that intake of Lp299v can increase iron absorption by over 100%% from an oat base with low iron bioavailability (contains high levels of phytic acid (PA)).

To examine the possibility that albumin may reduce RA levels (bioavailability) via direct binding, we transfected HSCs-P1 with expression vector for mutant albumin, in which three high-affinity fatty acid binding sites (Arg410, Tyr411, and Lys525), located in domain III, were substituted with an alanine residue (Kragh-Hansen et al, 2006).

Oral anticoagulant therapy with VKAs or novel oral anticoagulants, e.g. dabigatran and rivaroxaban, may also be problematic in patients with cancer because of drug interactions, malnutrition, vomiting and mucositis, and renal and liver dysfunction, all of which can lead to unpredictable bioavailability and variable levels of anticoagulation.